Please refer to the attachment
GUJTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts more than Nifty Microcap 250 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gujarat Themis Biosyn Ltd has filed its 44th Annual Report for FY2024-25 along with the notice for the AGM scheduled for September 12, 2025. The company reported revenue of Rs. 150.8 crore, EBITDA of Rs. 68.8 crore and profit after tax (PAT) of Rs. 48.8 crore for the year ended March 31, 2025, reflecting healthy margins despite some tender volatility and monsoon-related power disruptions. The company is executing a capex plan spanning a new R&D facility (Phase 1 commissioned), a dedicated API block (validation batches underway) and additional fermentation capacity. Key business items at the AGM include adoption of audited financial statements, declaration of dividend, re-designation of Dr. Sachin D. Patel as Managing Director for 5 years from July 1, 2025, commission payments to promoter directors and Independent Directors, and appointment of a new Independent Director Mr. Nihar Parikh. The stock is listed on both BSE and NSE (NSE listing effective February 25, 2025).
Strong profitability with EBITDA margin around 45% and PAT margin over 32% signals robust business health, while the leadership transition to Dr. Sachin D. Patel as MD and planned dividend declaration are positive for shareholders. Expansion into APIs and new fermentation capacity point to future growth potential, though execution of capex plans remains to be tracked.